A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Conditions
Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University Of Colorado, Aurora, Colorado, United States
Moffitt Cancer Center, Tampa, Florida, United States
Contact: Study coordinator (Supreet Kaur)Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Washington University School of Medicine in St. Louis, St Louis, Missouri, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Contact: Study coordinator (Grant Schofield)Memorial Sloan Kettering Cancer Center, New York, New York, United States
Cleveland Clinic, Cleveland, Ohio, United States
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Study coordinator (Nathan Denlinger)University of Pennsylvania, Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Ayushi Chauhan)Fred Hutchinson Cancer Center, Seattle, Washington, United States
Contact: Study coordinator (Vyshak Alva Venur)Local Institution - 0111, Nice, Alpes-Maritimes, France
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu, Nantes, Loire-Atlantique, France
Local Institution - 0103, Pierre-Bénite, Rhône, France
Local Institution - 0106, Dijon, France
Chru De Lille - Hopital Claude Huriez, Lille, France
Local Institution - 0112, Marseille, France
CHU Montpellier, Montpellier, France
Local Institution - 0114, Paris, France
Local Institution - 0102, Paris, France
Local Institution - 0108, Pessac, France
CHU de Rennes - Hopital de Pontchaillou, Rennes, France
Centre Henri Becquerel, Rouen, France
Contact: Study coordinator (Vincent Camus)Local Institution - 0110, Saint-Cloud, France
Local Institution - 0115, Strasbourg, France
Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole, Toulouse, France
Local Institution - 0116, Vandœuvre-lès-Nancy, France
Local Institution - 0202, Freiburg im Breisgau, Baden-Wurttemberg, Germany
Universitätsklinikum Ulm, Ulm, Baden-Wurttemberg, Germany
Universitätsklinikum Köln, Cologne, North Rhine-Westphalia, Germany
Contact: Study coordinator (Jan-Michel Heger)Universitätsklinikum Essen, Essen, North Rhine-Westphalia, Germany
Klinikum Chemnitz gGmbH, Chemnitz, Saxony, Germany
Charité - Universitätsmedizin Berlin, Berlin, Germany
Contact: Study coordinator (Björn Chapuy)Local Institution - 0207, Göttingen, Germany
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Contact: Study coordinator (Francis Ayuk)Universitätsklinikum Heidelberg, Heidelberg, Germany
Klinikum Stuttgart - Katharinenhospital, Stuttgart, Germany
Study leads
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb